# Fractionated Gyroscopic Radiosurgery for Optic Nerve Glioma: A Case Report and Review of the Literature

**Authors:** Parvathi Narayanaswamy, Alisha VP, Sapna V Manocha, Ganesh Jadhav, Rohit K Chaini, Sudheer Tyagi, Saji Oommen, Sunil Chauhan, Harish Kumar, Ankit Yadav

PMC · DOI: 10.7759/cureus.85112 · 2025-05-30

## TL;DR

A 20-year-old patient with optic nerve glioma was successfully treated with a new type of radiotherapy called gyroscopic radiosurgery, showing promising results with minimal side effects.

## Contribution

This is the first reported use of gyroscopic radiosurgery for treating optic nerve glioma.

## Key findings

- The treatment plan spared normal structures, potentially leading to better long-term outcomes.
- The patient showed good clinical control with no significant toxicity after one month.
- GRS may be considered as a first-line treatment option after further evaluation.

## Abstract

Radiotherapy offers a favorable long-term outcome for the treatment of optic pathway glioma, but at a cost of neurocognitive impairment and decreased quality of life. This has led to a chemotherapy-first approach, deferring radiotherapy till disease progression. We present a case report wherein a 20-year-old female patient with left optic nerve glioma was treated with definitive radiotherapy using a self-shielding gyroscopic radiosurgery (GRS) system. We report the first published use of GRS in the treatment of optic nerve glioma.

The patient was treated with 15 Gy at the 56% isodose line in two fractions on alternate days with 17 isocenters and 271 non-coplanar beams, amounting to a total treatment time of 63 minutes. The evaluation of the treatment plan shows considerable sparing of the normal structures, which may translate into better long-term clinical outcomes. A clinical follow-up after a month of treatment showed good clinical control without any undue treatment-related toxicity. Further follow-up is slated as per standard protocol. This case report opens up the potential for considering GRS after careful scrutiny as a first-line approach in the treatment of optic nerve glioma.

## Linked entities

- **Diseases:** optic nerve glioma (MONDO:0003235)

## Full-text entities

- **Diseases:** toxicity (MESH:D064420), neurocognitive impairment (MESH:D019965), Optic Nerve Glioma (MESH:D020339)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12207188/full.md

---
Source: https://tomesphere.com/paper/PMC12207188